Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-sig-hMUC-1/ecdCD40L vaccine for epithelial cancers
NCT02140996Phase 1Unknown
- Sponsor
- Singapore Clinical Research Institute
- Start
- Sep 2014
- Primary completion
- Mar 2017
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ad-sig-hMUC-1/ecdCD40L vaccine in breast cancer, ovarian cancer, lung cancer and 2 more, sponsored by Singapore Clinical Research Institute. Status: unknown.
02
Drugs
Ad-sig-hMUC-1/ecdCD40L vaccine
03
Conditions
breast cancerovarian cancerlung cancerprostate cancer (PCa)colon cancer
Beyond the preview
Go deeper on NCT02140996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140996.